Adjunctive recombinant human parathyroid hormone agents for the treatment of medication-related osteonecrosis of the jaw: a report of three cases
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Teriparatide has been effective in treating people diagnosed with medication-related osteonecrosis of the jaw (MRONJ). However, its efficacy is not well established to be accepted as a standard of care. The objective of this paper was to investigate the efficacy of recombinant human parathyroid hormone for the treatment of MRONJ. We report three cases of MRONJ patients with osteoporosis as the primary disease who were treated with a teriparatide agent along with other adjunctive measures. Each patient was administered a teriparatide injection subcutaneously for 16 weeks, 36 weeks, or 60 weeks. Surgical intervention including partial resection, sequestrectomy, decortication, and saucerization took place during the teriparatide administration. Complete lesion resolution was identified clinically and radiographically in all three patients. In patients diagnosed with MRONJ, teriparatide therapy is an efficacious and safe therapeutic option to improve healing of bone lesions. These findings demonstrate that teriparatide in combination with another therapy, especially bone morphogenetic protein, platelet-rich fibrin, or antibiotic therapy, can be an effective protocol for MRONJ.
Abstract
Teriparatide has been effective in treating people diagnosed with medication-related osteonecrosis of the jaw (MRONJ). However, its efficacy is not well established to be accepted as a standard of care. The objective of this paper was to investigate the efficacy of recombinant human parathyroid hormone for the treatment of MRONJ. We report three cases of MRONJ patients with osteoporosis as the primary disease who were treated with a teriparatide agent along with other adjunctive measures. Each patient was administered a teriparatide injection subcutaneously for 16 weeks, 36 weeks, or 60 weeks. Surgical intervention including partial resection, sequestrectomy, decortication, and saucerization took place during the teriparatide administration. Complete lesion resolution was identified clinically and radiographically in all three patients. In patients diagnosed with MRONJ, teriparatide therapy is an efficacious and safe therapeutic option to improve healing of bone lesions. These findings demonstrate that teriparatide in combination with another therapy, especially bone morphogenetic protein, platelet-rich fibrin, or antibiotic therapy, can be an effective protocol for MRONJ.
참고문헌 (18)
- Sim IW, "Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw : a placebo-controlled, randomized trial", J Clin Oncol, 38, pp.2971~2980 (2020)[DOI]
- Khan AA, "Case-based review of osteonecrosis of the jaw (ONJ)and application of the international recommendations for management from the International Task Force on ONJ", J Clin Densitom, 20, pp.8~24 (2017)[DOI]
- Rubin MR, "The anabolic effects of parathyroid hormone therapy", Clin Geriatr Med, 19, pp.415~432 (2003)[DOI]
- Eastell R, "Anabolic treatment for osteoporosis : teriparatide", Clin Cases Miner Bone Metab, 14, pp.173~178 (2017)[DOI]
- Dempster DW, "Anabolic actions of parathyroid hormone on bone", Endocr Rev, 14, pp.690~709 (1993)[DOI]
- Frost ML, "Differential effects of teriparatide on regional bone formation using(18)F-fluoride positron emission tomography", J Bone Miner Res, 26, pp.1002~1011 (2011)[DOI]
- "J Oral Maxillofac Surg", 2007, 573~580, 10.1016[DOI]
- Narongroeknawin P, "Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide : a review of the literature and a case report", Spec Care Dentist, 30, pp.77~82 (2010)[DOI]
- Iwamoto J, "Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis", Clin Drug Investig, 32, pp.547~553 (2012)[DOI]
- Kim KM, "Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw", Osteoporos Int, 25, pp.1625~1632 (2014)[DOI]
- Kakehashi H, "Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw : preliminary findings", Int J Oral Maxillofac Surg, 44, pp.1558~1564 (2015)[DOI]
- Dos Santos Ferreira L, "Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis", Osteoporos Int, 32, pp.2449~2459 (2021)[DOI]
- "injection) for subcutaneous use"[URL]
- Neer RM, "Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)[DOI]
- Morishita K, "Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw(MRONJ) : a multicenter retrospective analysis in Japan", J Orthop Sci, 25, pp.1079~1083 (2020)[DOI]
- Krege JH, "Teriparatide and osteosarcoma risk : history, science, elimination of boxed warning, and other label updates", JBMR Plus, 6, pp.e10665~ (2022)[DOI]
- Carlson ER, "The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws", J Oral Maxillofac Surg, 67(5 Suppl), pp.85~95 (2009)[DOI]
- Stockmann P, "The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months", Clin Oral Investig, 18, pp.1299~1304 (2014)[DOI]